Hospital.Help

Tainan – According to a new cohort study, the dual agonist tirzepatide reduces the overall mortality of people with type 2 diabetes compared to glucagon-like peptide 1 receptor agonists (GLP-1-RA). As researchers led by Min-Hsiang Chuang, Chi Mei Medical Center, Tainan, report in the journal JAMA Network Open, the therapy also improved cardiovascular and renal events (DOI:…